SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated December 2, 2024, serves as a notification to the market regarding the Company's total voting rights and capital structure. The report is issued in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. The data reflects the Company's issued share capital as of November 30, 2024.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (31 pence each) | 4,314,290,489 |
| Treasury Shares | 169,171,155 |
| Total Voting Rights | 4,145,119,334 |
Material Changes
The filing text does not provide comparative data against a prior period to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory notification intended to assist shareholders in calculating their interest thresholds under FCA rules.
Key Facts for Investor Verification
- Voting Rights Denominator: Shareholders should use the figure of 4,145,119,334 voting rights to determine if they are required to notify the Company of their interest or changes thereto.
- Treasury Holdings: Approximately 169.2 million shares are held in Treasury and do not carry voting rights.
- Share Class: The capital consists entirely of Ordinary Shares with a nominal value of 31 pence each.
- Contact for Notifications: Shareholder notifications should be directed to company.secretary@gsk.com.